Verify any claim · lenz.io
Claim analyzed
Health“A follow-up study of 382 adults younger than 60 years old, assessed 3 months after a first myocardial infarction and followed for 20 years, reported that participants in the highest tertile of interleukin-6 had a 2.70-fold higher risk of hospitalization for heart failure than those in the lowest tertile (hazard ratio 2.70; 95% CI 1.32–5.50).”
Submitted by Daring Owl df4c
The conclusion
Open in workbench →The reported hazard ratio appears in the literature, but the claim's age-specific framing is not reliably established. One abstract describes 382 adults younger than 60, yet other peer-reviewed sources assign the same 2.70 estimate and sample to patients aged 60–74, and a related report cites 391 participants. Because age materially affects interpretation, the statement overstates certainty about which cohort produced this result.
Caveats
- The age group is disputed: the same HR and sample size are reported elsewhere for patients aged 60–74, not younger than 60.
- A related publication reports 391 rather than 382 participants, suggesting overlapping cohorts or reporting inconsistency.
- The association is observational and model-dependent; it should not be read as proof that higher IL-6 directly causes heart-failure hospitalization.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
This 2025 randomized trial is unrelated to the claim’s interleukin-6 question, but it confirms that the PubMed result set provided here is not the target study. The abstract reports a cardiovascular outcomes trial of oral semaglutide with a primary endpoint of major adverse cardiovascular events, not a post-myocardial-infarction cytokine follow-up study.
This 2019 trial is also unrelated to the claim’s described cohort and endpoint. The abstract reports noninferiority for major adverse cardiovascular events in patients with type 2 diabetes, not a study of 382 adults younger than 60 years after first myocardial infarction.
We studied 382 patients younger than 60 years examined 3 months after a first myocardial infarction and followed them for almost 20 years. During follow-up we observed that those in the highest tertile of interleukin-6 had a 2.70-fold increased risk of hospitalization for heart failure compared with those in the lowest tertile (hazard ratio 2.70; 95% confidence interval 1.32–5.50).
In a prospective study of 391 patients younger than 60 years with a first myocardial infarction, we evaluated whether systemic markers of inflammation predicted long‑term risk of major cardiovascular events. Patients were evaluated 3 months after the acute event and followed for up to 20 years. "Participants in the highest tertile of interleukin‑6 had a 2.7‑fold increased risk of hospitalization for heart failure compared with those in the lowest tertile (hazard ratio 2.70; 95% CI, 1.32–5.50)." The association between IL‑6 levels and heart failure remained significant after adjustment for traditional risk factors.
BACKGROUND: We therefore examined the relation between IL-6 and the risk of HF after a first-evers MI during long-term follow-up in a cohort of 382 elderly (aged 60 to 74 years) patients with a first MI. METHODS AND RESULTS: IL-6 was determined in serum obtained 3 months after a first-evers MI in 382 patients. Patients were then followed up for a median of 19.6 years. Patients in the highest tertile of IL-6 had a higher risk of hospitalization for HF (hazard ratio 2.70; 95% CI 1.32 to 5.50) compared with those in the lowest tertile, after adjustment for traditional risk factors and NT-proBNP.
Summarizing cohort data, the review notes that higher circulating IL-6 concentrations are associated with incident heart failure and heart failure hospitalization in various populations. It cites studies in post–myocardial infarction patients where IL-6 levels stratified into tertiles or quartiles were independently related to later heart failure events, with higher categories showing several-fold increases in risk versus the lowest category.
Serum IL-6 was analysed in blood samples obtained 3 months after a first-evers MI in 382 patients aged 60–74 years. During a median follow up of 19.6 years, those in the highest tertile of IL-6 had a significantly increased risk of hospitalisation for heart failure compared with the lowest tertile (adjusted hazard ratio 2.70, 95% confidence interval 1.32 to 5.50). The association remained after adjustment for clinical risk factors and N-terminal pro-brain natriuretic peptide.
The present study shows that serum IL-6 is predictive of long-term cardiovascular events in symptomatic patients with stable coronary disease who have a high cardiovascular risk. Serum IL-6 measurements above 0.44 pg/mL increased the risk of cardiovascular events by 2.8 times (hazard ratio = 2.81; 95% CI 1.38–5.72, p = 0.01). Although this is a different population and follow-up period, it supports an association between higher IL-6 levels and adverse cardiovascular outcomes.
This meta-analysis aimed to explore the relationship between plasma interleukin-6 (IL-6) levels, adverse cardiovascular events, and the severity of acute coronary syndrome. Across included studies, higher IL-6 levels were associated with an increased risk of major adverse cardiovascular events (pooled relative risk 2.09, 95% CI 1.65–2.65), indicating that elevated IL-6 is consistently linked to worse long-term outcomes after coronary events.
Among older adults in the Atherosclerosis Risk in Communities (ARIC) study, higher levels of interleukin-6 were significantly associated with global cardiovascular disease, which included coronary heart disease, stroke and heart failure hospitalization. The hazard ratio for global cardiovascular disease per log unit increase in IL-6 was 1.57 (95% CI 1.44–1.72), and IL-6 also increased risk for heart failure hospitalization specifically after multivariable adjustment.
In this cohort of patients recently hospitalized with HFpEF, IL-6 was an independent predictor of all-cause mortality, cardiovascular death, and subsequent heart failure hospitalization after adjustment for clinical risk factors including B-type natriuretic peptide. When assessed continuously, each 1 log unit increase in IL-6 was associated with a higher risk of subsequent heart failure hospitalization (hazard ratio 1.24; 95% CI 1.01–1.51).
In 5346 patients stabilized after an acute coronary syndrome, IL-6 levels were measured and patients were followed for a median of 2.5 years for cardiovascular death or heart failure hospitalization. For every standard deviation increase in IL-6, there was a 22% higher risk of cardiovascular death or heart failure (adjusted hazard ratio 1.22, 95% CI 1.11–1.34), and patients in the highest IL-6 quartile had an adjusted hazard ratio of 2.29 (95% CI 1.60–3.29) for cardiovascular death or heart failure compared with the lowest quartile.
In a cohort of patients with cardiogenic shock following acute myocardial infarction, IL-6 concentrations were measured on admission. The authors report that IL-6 was the strongest independent predictor of 30-day mortality among several biomarkers, highlighting the prognostic importance of IL-6 in the setting of myocardial infarction, though long-term heart-failure hospitalization was not assessed.
A well-known cohort paper reported that 382 survivors of a first myocardial infarction, all younger than 60 years and examined about 3 months after the event, were followed for up to 20 years. In that study, higher interleukin-6 was associated with later hospitalization for heart failure, with the highest tertile showing a hazard ratio of 2.70 and a 95% confidence interval of 1.32 to 5.50 versus the lowest tertile.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
The claim is directly validated by Source 3, which confirms that a study of 382 patients younger than 60 years assessed 3 months after a first myocardial infarction and followed for nearly 20 years found those in the highest interleukin-6 tertile had a 2.70-fold higher risk of heart failure hospitalization (HR 2.70; 95% CI 1.32–5.50). This exact cohort size, age threshold, follow-up period, and hazard ratio are further corroborated by Source 4 and Source 14, establishing the absolute accuracy of the claim.
The Proponent's reliance on Source 3 as definitive validation is undermined by the irreconcilable conflict with Sources 5 and 7, which report the identical sample size of 382 patients, the same 3-month post-MI assessment, the same ~20-year follow-up, and the exact same hazard ratio of 2.70 (95% CI 1.32–5.50), yet explicitly characterize the cohort as 'elderly (aged 60 to 74 years)' — the precise opposite of the 'younger than 60' criterion the claim asserts. The Proponent's appeal to Source 14 as corroboration is a weak authority fallacy, as Source 14 is explicitly labeled LLM Background Knowledge of unknown date and lowest authority among all sources, and cannot resolve the direct empirical contradiction between Source 3 and Sources 5 and 7 regarding the cohort's age range.
Argument against
The claim specifies a cohort of adults 'younger than 60 years old,' but Sources 5 and 7 — which match the identical sample size of 382 patients, the same 3-month post-MI assessment, the same ~20-year follow-up, and the exact same hazard ratio of 2.70 (95% CI 1.32–5.50) — explicitly describe the cohort as 'elderly (aged 60 to 74 years),' directly contradicting the age criterion stated in the claim. Furthermore, Source 4, which also reports the same hazard ratio and study parameters, describes a cohort of 391 patients rather than 382, introducing additional inconsistency that undermines confidence in the precise demographic details asserted by the claim.
The Opponent's argument relies on a false dichotomy by claiming that the age demographic is contradicted, whereas Source 3 explicitly confirms the exact cohort of 382 patients "younger than 60 years" with the identical 2.70 hazard ratio and 20-year follow-up. By focusing on the elderly cohorts in Sources 5 and 7, the Opponent commits a straw man fallacy, ignoring that Source 3 and Source 14 directly validate the precise age, sample size, and statistical parameters asserted in the claim.
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The claim's specific parameters (382 patients, younger than 60, 20-year follow-up, HR 2.70) are directly supported by Source 3, but this exact statistical output and sample size are also attributed to an elderly cohort (60-74 years) in Sources 5 and 7, and a 391-patient cohort in Source 4. This logical contradiction across peer-reviewed sources indicates a significant data-conflation or reporting error in the literature, meaning the claim's specific demographic-statistical pairing is misleadingly represented.
Expert 2 — The Context Analyst
The claim accurately reproduces the cohort size, timing (3 months post–first MI), follow-up duration, endpoint, and effect estimate reported in the PubMed abstract for a <60-year cohort (HR 2.70; 95% CI 1.32–5.50) (Source 3), but it omits that essentially the same IL-6/heart-failure result is also reported in a separate paper explicitly describing an older (60–74) cohort (Sources 5,7), and another closely related report cites 391 patients (Source 4), which can confuse which population the HR pertains to. With that context restored, the specific statement about a <60-year follow-up study reporting this HR remains supported by Source 3 and is therefore mostly accurate, though the literature's overlapping cohorts/duplicate-looking estimates make the framing less clear than the claim implies.
Expert 3 — The Source Auditor
Source 3 (PubMed, high-authority, 2005) directly and precisely matches every element of the claim — 382 patients younger than 60 years, assessed 3 months post-first MI, followed for nearly 20 years, with HR 2.70 (95% CI 1.32–5.50) for heart failure hospitalization in the highest IL-6 tertile. However, Sources 5 and 7 (both high-authority PubMed/PMC entries) report the identical sample size of 382, the same 3-month assessment, the same ~20-year follow-up, and the exact same HR 2.70 (95% CI 1.32–5.50), but explicitly describe the cohort as 'elderly (aged 60 to 74 years)' — the direct opposite of the claim's 'younger than 60' criterion. This creates a genuine empirical conflict among high-authority sources: Source 3 supports the claim's age characterization while Sources 5 and 7 contradict it, and Source 14 (LLM background knowledge, lowest authority, unknown date) cannot resolve this contradiction. Source 4 introduces further inconsistency by reporting 391 patients rather than 382. The most parsimonious explanation is that Sources 5 and 7 describe the actual primary study (with the elderly cohort), while Source 3's snippet may reflect a different or mischaracterized study, or there is a data extraction error in one of the PubMed records — but given that two independent high-authority sources (5 and 7) agree on the elderly age range versus one source (3) supporting the younger-than-60 characterization, the claim's age criterion is at minimum contested by credible evidence, rendering the claim misleading as stated.